Galapagos UK Michael Smyth joins the pharmaphorum podcast for our latest episode to talk about joining the company as medical director just as COVID-19 hit.
We spoke in episode 35 of the podcast about the pandemic’s impact on his role and the company, and about RNA-based technology, which has hit the headlines in recent months due to its use in COVID vaccines.
Michael discussed the version of RNA-based technology that Galapagos is focusing on and how it can produce compounds that might alter the course of a disease.
We also looked at some of the UK launch challenges pharma can face with innovative therapies and the types of evidence that HTA bodies like NICE need for RNA-based drugs.
Meanwhile, in episode 34 pharmaphorum’s website editor Catherine Longworth spoke with Mogrify’s CEO Dr Darrin Disley about big data and cell therapy development.
The UK biotech company wants to transform the development of cell therapies using a systematic direct cell conversion and maintenance platform powered by big-data and Darrin discussed the story behind Mogrify’s technology.
You can listen to episode 35 of the pharmaphorum podcast here and episode 34 here, or download them from iTunes, Spotify, acast, Stitcher and Podbean, where you can also subscribe to the entire series.
Dominic Tyer 